Advertisement
New Zealand markets close in 36 minutes
  • NZX 50

    11,710.00
    +27.50 (+0.24%)
     
  • NZD/USD

    0.6132
    -0.0020 (-0.32%)
     
  • NZD/EUR

    0.5647
    -0.0014 (-0.25%)
     
  • ALL ORDS

    7,935.70
    -99.20 (-1.23%)
     
  • ASX 200

    7,666.10
    -100.60 (-1.30%)
     
  • OIL

    80.11
    +0.28 (+0.35%)
     
  • GOLD

    2,358.90
    +2.40 (+0.10%)
     
  • NASDAQ

    18,869.44
    +61.14 (+0.33%)
     
  • FTSE

    8,254.18
    -63.41 (-0.76%)
     
  • Dow Jones

    38,852.86
    -216.74 (-0.55%)
     
  • DAX

    18,677.87
    -96.83 (-0.52%)
     
  • Hang Seng

    18,531.29
    -289.87 (-1.54%)
     
  • NIKKEI 225

    38,690.08
    -165.29 (-0.43%)
     
  • NZD/JPY

    96.4440
    -0.0070 (-0.01%)
     

BioCryst to Present at Upcoming Investor Conferences

BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc.

RESEARCH TRIANGLE PARK, N.C., May 07, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the following conferences:

  • Citizens JMP Life Sciences Conference in New York on Monday, May 13, 2024, at 12:30 p.m. ET.

  • 2024 RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 14, 2024, at 3:05 p.m. ET.

  • Bank of America Health Care Conference 2024 in Las Vegas on Wednesday, May 15, 2024, at 5:20 p.m. ET.

  • H.C. Wainwright 2nd Annual BioConnect Investor Conference in New York on Monday, May 20, 2024, at 10:30 a.m. ET.

ADVERTISEMENT
  • Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024, at 9:30 a.m. ET.

Links to the live audio webcasts and replays of the presentations may be accessed in the Investors & Media section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with complement-mediated and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com